![Pharmaceutics | Free Full-Text | A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes Pharmaceutics | Free Full-Text | A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes](https://www.mdpi.com/pharmaceutics/pharmaceutics-13-00485/article_deploy/html/images/pharmaceutics-13-00485-g001-550.jpg)
Pharmaceutics | Free Full-Text | A Model-Informed Drug Development (MIDD) Approach for a Low Dose of Empagliflozin in Patients with Type 1 Diabetes
U.S. FDA approves first-in-class Glyxambi® (empagliflozin/linagliptin) tablets for adults with type 2 diabetes
![Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes - Media Centre | EASD Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/546_706079_1/Slide4.jpg)
Fixed dose combinations of empagliflozin/linagliptin for 52 weeks as add-on to metformin in subjects with type 2 diabetes - Media Centre | EASD
![The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01659-1/MediaObjects/41591_2021_1659_Fig1_HTML.png)